QSV Biologics and Alseres Pharmaceuticals have signed a contract for the process development and cGMP manufacture of Cethrin for spinal cord injury. QSV will be responsible for technology transfer, process development and cGMP manufacture of Phase IIb/III clinical trial material. Alseres licensed the drug from BioAxone Therapeutics. Cethrin is a Rho inhibitor that stimulates axon regeneration. Dr. Graeme Macaloney, QSV president and chief executive officer said, “This first-in-field t...